Maharshi Sudhir, Sharma Barjesh Chander, Sachdeva Sanjeev, Srivastava Siddharth, Sharma Praveen
Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
Department of Gastroenterology, G.B. Pant Hospital, New Delhi, India.
Clin Gastroenterol Hepatol. 2016 Mar;14(3):454-460.e3; quiz e33. doi: 10.1016/j.cgh.2015.09.028. Epub 2015 Oct 8.
BACKGROUND & AIMS: Minimal hepatic encephalopathy (MHE) impairs health-related quality of life (HRQOL), leads to the development of overt HE, and is associated with poor outcome. We performed a randomized controlled trial to assess the effects of nutritional therapy on cognitive functions and HRQOL in patients with cirrhosis with MHE.
In a tertiary care setting in New Delhi, India, patients with cirrhosis with MHE were assigned randomly to groups given nutritional therapy (30-35 kcal/kg/d, 1.0-1.5 g vegetable protein/kg/d; n = 60; age, 42.1 ± 10.3 y; 48 men) or no nutritional therapy (patients continued on their same diet; n = 60; age, 42.4 ± 9.6 y; 47 men) for 6 months in 2014. MHE was diagnosed based on their psychometry hepatic encephalopathy score (PHES). HRQOL was assessed by a sickness impact profile (SIP) questionnaire. Primary end points were improvement or worsening in MHE and improvement in HRQOL.
There was no significant difference in baseline PHES (-8.12 ± 1.32 vs -8.53 ± 1.38; P = .08) or SIP (14.25 ± 5.8 vs 15.44 ± 5.03; P = .85) scores. After the 6-month study period, a higher proportion of patients in the nutritional therapy group had reversal of MHE (71.1% vs 22.8%; P = .001). Patients in the nutritional therapy group also had larger increases in PHES (3.86 ± 3.58 vs 0.52 ± 4.09; P = .001) and HRQOL (improvement in SIP score of 3.24 ± 3.63 vs 0.54 ± 3.58; P = .001). Overt HE developed in 10% of patients in the nutritional therapy group vs 21.7% of the control group (P = .04).
Based on a randomized controlled trial performed in India, nutritional therapy is effective in the treatment of MHE and is associated with improvement in HRQOL. Clinical Trial Registry-India registration no: CTRI/2013/07/003851.
轻微肝性脑病(MHE)会损害健康相关生活质量(HRQOL),导致显性肝性脑病(HE)的发生,并与不良预后相关。我们进行了一项随机对照试验,以评估营养治疗对肝硬化合并MHE患者认知功能和HRQOL的影响。
在印度新德里的一家三级医疗机构中,2014年将肝硬化合并MHE的患者随机分为接受营养治疗组(30 - 35千卡/千克/天,1.0 - 1.5克植物蛋白/千克/天;n = 60;年龄42.1±10.3岁;48名男性)或不接受营养治疗组(患者继续原饮食;n = 60;年龄42.4±9.6岁;47名男性),为期6个月。根据心理测量肝性脑病评分(PHES)诊断MHE。通过疾病影响概况(SIP)问卷评估HRQOL。主要终点是MHE的改善或恶化以及HRQOL的改善。
基线PHES(-8.12±1.32 vs -8.53±1.38;P = 0.08)或SIP(14.25±5.8 vs 15.44±5.03;P = 0.85)评分无显著差异。在为期6个月的研究期后,营养治疗组中更多比例的患者MHE得到逆转(71.1% vs 22.8%;P = 0.001)。营养治疗组患者的PHES升高幅度也更大(3.86±3.58 vs 0.52±4.09;P = 0.001),HRQOL也有更大改善(SIP评分改善3.24±3.63 vs 0.54±3.58;P = 0.001)。营养治疗组10%的患者发生显性HE,而对照组为21.7%(P = 0.04)。
基于在印度进行的一项随机对照试验,营养治疗对MHE的治疗有效,并与HRQOL的改善相关。印度临床试验注册中心注册号:CTRI/2013/07/003851。